SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 15, 2013

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

De laware (State or other jurisdiction of incorporation)

000-51891 (Commission File Number) 20-4494098 (IRS Employer Identification Number)

5950 Priestly Drive, Carlsbad, CA 92008 (Address of principal executive offices, including zip code)

(760) 940-6383 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following isions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers	Election of Directors;	Appointment of Certain	Officers; Compensatory	Arrangements of
Certain Officers				

(b) On September 15, 2013, James H. Berglund notified International Stem Cell Corporation (the "Company") of his resignation from the Board of Directors of the Company effective September 15, 2013. Mr. Berglund did not state that his resignation from the Board was due to any disagreement with the Company.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Stem Cell Corporation

By: /s/ Jay Novak

Jay Novak Interim Chief Financial Officer

Dated: September 19, 2013